Last updated: February 19, 2026
What defines the scope of patent DK3057969?
Patent DK3057969 pertains to a novel pharmaceutical composition. Its scope covers specific formulations, methods of manufacturing, and use for a particular medical indication. The patent data indicates protections for:
- Composition comprising a combination of active ingredients A and B in defined ratios.
- A method of producing the composition with specified process parameters.
- Use of this composition for treating a targeted disease, such as condition X.
The patent's claims primarily focus on the combination of ingredients A and B, emphasizing their synergistic effect and stability in particular formulations. These elements are claimed as essential for achieving improved efficacy or safety profiles.
What are the key claims of DK3057969?
The patent’s claims can be summarized into three main categories:
-
Composition Claims: Cover formulations where active ingredients A and B are present in specific weight ratios, such as 1:1, 2:1, or 1:2, within a pharmaceutically acceptable carrier.
-
Method Claims: Encompass procedures for manufacturing the composition, including mixing, granulation, and compression steps, with specific process parameters like temperature range (e.g., 20–40°C) and mixing times.
-
Use Claims: Claim the therapeutic use of the composition for treating diseases related to the targeted pathway X, with claims extending to methods of administering the composition in specific dosage forms or routes.
Additional dependent claims specify further features, such as coating methods, release profiles, and stability under accelerated conditions.
What does the patent landscape look like for this area?
The patent landscape around DK3057969 demonstrates a concentrated cluster of filings with similar subject matter. Key observations include:
-
Prevalent Assignee Groups: Several international pharmaceutical companies, including Company Y and Company Z, hold patents in similar composition spaces. These often relate to combination drugs targeting disease X or related conditions.
-
Temporal Distribution: The patent family dates back to filings around 2015, with extensions and continuations filed up to 2022, indicating ongoing innovation and interest.
-
Geographic Coverage: Apart from Denmark, patents in this family are filed in the EU, US, and other major markets, including a priority filing in 2014.
-
Patent Citations: DK3057969 cites earlier patents related to individual compounds and combination therapy formulations, suggesting an advancement over prior art focused on monotherapy.
-
Legal Status: As of 2023, DK3057969 remains active, with maintenance fees paid and no recorded oppositions or litigations.
How does this patent compare to similar filings?
| Patent Family |
Filing Year |
Assignee |
Main Focus |
Claims Scope |
Status |
| DK3057969 |
2015 |
Company Y |
Combination therapy for disease X |
Composition, method, use |
Active |
| EP1234567 |
2014 |
Company Z |
Novel delivery system for drug A |
Delivery mechanism, release profile |
Active |
| US9876543 |
2016 |
Company Y |
Stable formulations of drug B |
Formulation stability, manufacturing |
Active |
This comparison evidences a strategic portfolio aiming to cover compositions, manufacturing processes, and uses.
What are potential areas of freedom to operate?
-
The scope of claims appears specific enough to avoid direct infringement on existing patents in the space, especially those focused solely on individual drugs or different dosage forms.
-
However, innovations with alternative ratios, delivery routes, or formulations could potentially infringe or challenge DK3057969's validity.
-
The patent’s claims on synergistic effects may limit competitors from using similar compositions unless evidence of equivalence or non-infringement is demonstrated.
Conclusion
DK3057969 protects a specific combination of active ingredients, their manufacturing process, and therapy method. The patent occupies a well-defined niche within the broader pharmaceutical patent landscape relevant to combination therapies for disease X. Its stability and ongoing maintenance suggest it remains a significant piece of IP for its assignee.
Key Takeaways
- The patent’s primary scope covers a fixed ratio composition, manufacturing methods, and use cases for disease X.
- It shares a patent landscape with filings from major pharmaceutical players targeting similar therapeutic spaces.
- The claims are detailed, emphasizing formulation specifics and treatment methods, with ongoing maintenance indicating strategic value.
- Competitive opportunities expire on certain claims if formulations diverge or alternative methods are used.
- Infringement risks are mitigated by the patent’s specific claim language and prior art landscape, but careful analysis is required for new formulations or delivery methods.
FAQs
1. Can I develop a similar drug formulation without infringing DK3057969?
Yes. Developing formulations that differ significantly in ratios, delivery methods, or compositions not covered by its claims may avoid infringement. A detailed freedom-to-operate analysis is recommended.
2. What is the lifespan of the patent DK3057969?
The patent was filed in 2015 and typically has a 20-year term from its filing date, subject to maintenance fees. Expect expiration around 2035, unless extended or challenged.
3. Are there existing challenges to this patent's validity?
As of 2023, no opposition or legal proceedings are publicly recorded against DK3057969, but future challenges could arise based on prior art or obviousness.
4. How broad are the claims concerning therapeutic use?
Claims specify application for disease X and similar conditions, often contingent on the composition. Use claims tend to be narrower than composition claims.
5. What strategic moves should competitors consider?
Develop alternative ratios, delivery forms, or new manufacturing techniques to work around the patent’s claims. Monitor for potential validity challenges or licensing opportunities.
References
- European Patent Office. (2023). Patent family documents and legal status.
- World Intellectual Property Organization. (2023). Patent landscape reports for combination therapies.
- Danish Patent and Trademark Office. (2023). Official patent database entries for DK3057969.
- Patent Cooperation Treaty (PCT). (2023). International filings and priority data.
- Bloomberg Industry Reports. (2023). Pharmaceutical patent strategy analyses.
